These biospecimens will be interrogated to characterize effects on tumor and normal tissue radiation injury and immune activation and to assess for potential biomarkers of response or toxicity after Lu-177 PSMA RLT and HDR brachytherapy. The gene discussed is FOLH1; the disease is neoplasm.